ArticlemBio2024
A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting
Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- WHO assessment of the preclinical antifungal pipeline: evaluating innovation and preparedness in the face of emerging fungal threats.The Lancet. Microbe · 2026Review
- Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis.Frontiers in immunology · 2026Article
- Immune evasion, dysregulation, and emerging immunotherapies for invasive fungal infections in the immunocompromised host.Frontiers in immunology · 2026Review
- Review
- CAR-T Therapy Can Be a Useful Treatment Modality for More Than Just Hematologic Malignancies.Internal medicine (Tokyo, Japan) · 2026Review
- CAR-T therapy: Advances in respiratory diseases.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Immune genes CD247 STAT1 and LCK mediate host-pathogen interactions in sporotrichosis.Scientific reports · 2025Article
- Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Immunoengineering: An Emerging Field in Infectious Diseases.The Journal of infectious diseases · 2025Review
- Neutralizing Antibodies: Role in Immune Response and Viral Vector Based Gene Therapy.International journal of molecular sciences · 2025Review
- Hypoxia and HIF-1 inhibition enhance lentiviral transduction efficiency: a novel strategy for gene delivery optimization.BMC biotechnology · 2025Article
- Unlocking the Role of Treg Cells Immune Response and Infectious Risk Following CAR T-Cell Therapy in Patients with Cancer.International journal of molecular sciences · 2025Review
- Detection and Management of Invasive Mold Disease in Pediatric Hematological Cancer Patients.Infection and drug resistance · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Invasive aspergillosis (IA) is a common and deadly mold infection in immunocompromised patients. As morbidity and mortality of IA are primarily driven by poor immune defense, adjunct immunotherapies, such as chimeric antigen receptor (CAR) T cells, are direly needed. Here, we propose a novel approach to generate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.